DJ-1 and Parkin Modulate Dopamine-dependent Behavior and Inhibit MPTP-induced Nigral Dopamine Neuron Loss in Mice
Overview
Pharmacology
Affiliations
Parkin-deficient animals exhibit mitochondrial degeneration and increased oxidative stress vulnerability, and both mice and flies lacking DJ-1 are hypersensitive to environmental toxins associated with Parkinson's disease (PD). We used recombinant adeno-associated virus (AAV) gene transfer to study the influence of DJ-1 and Parkin on the dopaminergic system of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, a model for sporadic PD. After MPTP lesioning, significantly more dopamine neurons survived in the virus-injected substantia nigra of the AAV-DJ-1 and AAV-Parkin mice when compared with AAV-enhanced green fluorescent protein injected controls. Protection at the neuronal level was supported by increased amphetamine-induced contralateral turning behavior. Normal mice expressing DJ-1 showed apomorphine-induced ipsilateral turning, suggesting a hyporesponsiveness of striatal dopamine D1 receptors in the DJ-1-expressing hemisphere. MPTP drastically reduced dopamine to 19% of normal levels and neither DJ-1 nor Parkin protected against MPTP-induced catecholamine loss under these conditions. Our results show that Parkin and DJ-1 inhibit dopamine neuron death and enhance amphetamine-induced dopaminergic function in a mouse model of idiopathic PD. However, DJ-1 overexpression also reduced postsynaptic dopamine receptor responses in normal mice. These results warrant further exploration of DJ-1 and Parkin gene therapy for PD, although a better understanding of their effects on behavior and dopamine neurotransmission is required before these proteins can be safely used.
Zuo X, Bai H, Zhao Q, Zhang S, Zhao X, Feng X Mol Neurobiol. 2024; 62(3):3053-3066.
PMID: 39222261 DOI: 10.1007/s12035-024-04455-3.
Mayer C, Riera-Ponsati L, Kauppinen S, Klitgaard H, Erler J, Hansen S Front Pharmacol. 2024; 15:1437939.
PMID: 39119604 PMC: 11306042. DOI: 10.3389/fphar.2024.1437939.
Gassowska-Dobrowolska M, Olech-Kochanczyk G, Culmsee C, Adamczyk A J Inflamm Res. 2024; 17:4549-4574.
PMID: 39011416 PMC: 11249072. DOI: 10.2147/JIR.S468609.
Oxidative Stress and Antioxidants in Neurodegenerative Disorders.
Olufunmilayo E, Gerke-Duncan M, Holsinger R Antioxidants (Basel). 2023; 12(2).
PMID: 36830075 PMC: 9952099. DOI: 10.3390/antiox12020517.
Unraveling Parkinson's Disease Neurodegeneration: Does Aging Hold the Clues?.
Coleman C, Martin I J Parkinsons Dis. 2022; 12(8):2321-2338.
PMID: 36278358 PMC: 9837701. DOI: 10.3233/JPD-223363.